Table
2: Phase
III randomized, controlled trials investigating continuation maintenance
therapy.
Trial |
Induction
chemotherapy |
Maintenance
regimen |
Median
PFS |
Median
OS |
CECOG, Brodowicz et al. Lung Cancer 2006 [22] |
Cisplatin + gemcitabine ×
4 cycles |
Gemcitabine vs. BSC |
3.6 vs. 2.0 months, p < 0.001 |
13.0 vs. 11.0 months, p = 0.195 |
Belani et al. 2010 [23] |
Carboplatin + gemcitabine ×
4 cycles |
Gemcitabine vs. BSC |
3.9 vs. 3.8 months, p = 0.58 |
8.0 vs. 9.3 months, p
= 0.84 |
Perol et al. JCO 2012 [16] |
Cisplatin + gemcitabine × 4
cycles |
Gemcitabine vs. placebo (vs. erlotinib) |
3.8 vs. 1.9 months, p < 0.001 |
12.1 vs. 10.8 months, p = 0.3867 |
Cisplatin + pemetrexed× 4
cycles |
Pemetrexed vs. placebo |
4.1 vs. 2.8 months, p < 0.0001 |
13.9 vs. 11.0 months, p = 0.0195 |
|
Cisplatin + pemetrexed +
bevacizumab × 4 cycles |
Bevacizumab + pemetrexed
vs. bevacizumab |
7.4 vs. 3.7 months, p < 0.0001 |
17.1 vs. 13.2 months, p = 0.29 |
|
Point Break, Patel et al. JCO 2013 [19] |
Carboplatin + bevacizumab
+ (pemetrexed vs. paclitaxel) × 4 cycles |
Maintenance of non-carbo
therapy: Bev + (pemetrexed vs. paclitaxel) |
6.0 vs. 5.6 months, p = 0.012 |
12.6 vs. 13.4 months, p = 0.949 |